No abstract

No abstract

Nowadays the health care systems over the world are in a critical period trying to take control over the pandemic of COVID-19. The Bulgarian the Government introduced rapidly (8-to March 2020), restrictive control measures including general lockdown and social distancing. Despite several clinical trials, there are still no specific therapies or any vaccine against COVID-19. The only option available is using investigational drugs for compassionate use (CU). The global pandemic mandates Bulgarian Drug Agency (BDA) for a reasonable update of the existing national regulation concerning CU and off-label therapies. The update of the existing national regulation regarding CU is vital to ensure the effective and sustainable development of health policies and technologies over the COVID-19 pandemic and beyond.

Modern rehabilitation is based on the International Classification of Functioning, Disability and Health (ICF). We will discuss this Classification process in frailty. Frailty is defined as a condition of reduced functional reserve, a state of vulnerability that involves poor recovery of homeostasis and increased susceptibility to stressor mechanisms, with consequent difficulty in returning to the previous condition of balance. Rehabilitation of frailty is reported in the ICF, although, its consensus is not sufficiently addressed due to its recent identification and the limited available information regarding how it should be formulated. Thus, the aim of the present article is to present the current evidence-based rehabilitation strategies applied in management of frailty.